Download Section
Agenda
Agenda
Press Release
Press Release
Fact Sheets
Type 2 diabetes
Linagliptin in type 2 diabetes
Renal disease in type 2 diabetes
Visuals
Diabetes Complications
Boehringer Ingelheim's Commitment
Type 2 Diabetes Prevalence
Kidney Disease in Diabetes
Barriers to Glycaemic Control
Videos
Mode of Action of DPP-4 Inhibitors
(Watch on iPhone/iPad)
Diabetes Complications Animation
(Watch on iPhone/iPad)
Contact
Ute Schmidt

Corporate Communications
Boehringer Ingelheim GmbH
55216 Ingelheim / Germany

Phone: +49-6132-77 97296
Fax: +49-6132-72 6601

press@boehringer-ingelheim.com
Please be advised: Linagliptin is an investigational compound and not approved for clinical use. Please be aware that there may be national differences between countries regarding specific medical information, including licenced uses. Please take into account the information here is designed to supply you with current news in pharmaceutical and medical research and not to promote clinical use of the substances mentioned on this site.
Dr. Michael Mark, Boehringer Ingelheim (iPhone/iPad)
Dr. Steven E. Kahn, U.S.A. (iPhone/iPad) - Biography
Prof. Michael Nauck, Germany (iPhone/iPad) - Biography
Prof. Anthony Barnett, UK (iPhone/iPad) - Biography
Terms of use    Imprint